Meanwhile, OI type III and type IV and COL1A2 mutation were positively correlated with a longer duration of BP treatment to achieve the drug holiday, while patients with a later onset of BP treatment and severe clinical phenotypes were associated with a higher risk of BP retreatment. Here, COL1A2 is linked to osteogenesis imperfecta type 3.